Related Experiment Videos
Lung phosphodiesterase isoenzymes
1Department of Physiology and Pharmacology, University of Strathclyde, Glasgow, UK.
Agents and Actions. Supplements
|January 1, 1993
Summary
Protein kinase A activates lung Type V cyclic GMP phosphodiesterase, altering its function and reducing sensitivity to zaprinast inhibition. This suggests a regulatory role for protein kinase A in cyclic GMP hydrolysis.
Area of Science:
- Biochemistry
- Pharmacology
- Cellular Biology
Background:
- Phosphodiesterases (PDEs) regulate intracellular cyclic nucleotide levels.
- Cyclic GMP phosphodiesterase (PDE) activity is crucial in various physiological processes.
- Understanding PDE isoenzyme regulation is key to developing targeted therapeutics.
Purpose of the Study:
- To identify and characterize phosphodiesterase isoenzyme activities in guinea-pig lung.
- To investigate the role of protein kinase A in regulating Type V cyclic GMP phosphodiesterase.
- To elucidate the mechanism of PDE activation and its effect on inhibitor sensitivity.
Main Methods:
- Enzyme activity assays to measure phosphodiesterase hydrolysis rates.
- Kinetic analysis to determine changes in Vmax and inhibitor constants.
- Biochemical characterization of PDE isoenzymes in lung tissue.
Main Results:
- Distinct phosphodiesterase isoenzyme activities were identified in guinea-pig lung.
- Protein kinase A was shown to catalyze the activation of Type V cyclic GMP phosphodiesterase.
- Activation by protein kinase A resulted in a significant increase in Vmax and reduced sensitivity to zaprinast inhibition.
Conclusions:
- Protein kinase A plays a significant role in modulating Type V cyclic GMP phosphodiesterase activity.
- Activation involves alterations in the regulatory properties of a non-catalytic cyclic GMP binding site.
- These findings provide insights into the regulation of cyclic GMP metabolism in the lung.